UA96941C2 - Схема дозування кладрибіну для лікування розсіяного склерозу - Google Patents

Схема дозування кладрибіну для лікування розсіяного склерозу

Info

Publication number
UA96941C2
UA96941C2 UAA200813662A UAA200813662A UA96941C2 UA 96941 C2 UA96941 C2 UA 96941C2 UA A200813662 A UAA200813662 A UA A200813662A UA A200813662 A UAA200813662 A UA A200813662A UA 96941 C2 UA96941 C2 UA 96941C2
Authority
UA
Ukraine
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
UAA200813662A
Other languages
English (en)
Russian (ru)
Inventor
Х. Джеймс Джр. Бренцель
Мария Лопез-Бреснахан
Назих Аммоури
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of UA96941C2 publication Critical patent/UA96941C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується застосування багаторазових доз кладрибіну в комбінації з бета-інтерфероном для лікування розсіяного склерозу у пацієнтів, які резистентні принаймні до одного загальноприйнятого лікування.
UAA200813662A 2006-05-24 2007-05-23 Схема дозування кладрибіну для лікування розсіяного склерозу UA96941C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06114537 2006-05-24

Publications (1)

Publication Number Publication Date
UA96941C2 true UA96941C2 (uk) 2011-12-26

Family

ID=37395884

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200813662A UA96941C2 (uk) 2006-05-24 2007-05-23 Схема дозування кладрибіну для лікування розсіяного склерозу

Country Status (12)

Country Link
CN (1) CN101500598A (uk)
AT (1) ATE555804T1 (uk)
BR (1) BRPI0710326A2 (uk)
DK (1) DK2026832T3 (uk)
EC (1) ECSP088997A (uk)
ES (1) ES2384399T3 (uk)
MY (1) MY149042A (uk)
NZ (1) NZ572680A (uk)
PT (1) PT2026832E (uk)
RS (1) RS52424B (uk)
SI (1) SI2026832T1 (uk)
UA (1) UA96941C2 (uk)

Also Published As

Publication number Publication date
CN101500598A (zh) 2009-08-05
PT2026832E (pt) 2012-06-01
NZ572680A (en) 2011-11-25
BRPI0710326A2 (pt) 2011-08-09
DK2026832T3 (da) 2012-06-25
SI2026832T1 (sl) 2012-07-31
ECSP088997A (es) 2009-01-30
RS52424B (en) 2013-02-28
MY149042A (en) 2013-07-15
ATE555804T1 (de) 2012-05-15
ES2384399T3 (es) 2012-07-04

Similar Documents

Publication Publication Date Title
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
MY162067A (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
NZ611108A (en) Methods of treating fgf21-associated disorders
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MY172012A (en) Use of dpp iv inhibitors
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
HK1142270A1 (en) Silibinin component for the treatment of hepatitis
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
MY150931A (en) Substituted oxazolidinones and their use
NZ705124A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
MY149042A (en) Cladribine regimen for treating multiple sclerosis
BRPI0702847A (pt) formas de dosagem unitária de temozolomida
Fukumoto et al. New hope for Nutlin-3a therapy for pulmonary arterial hypertension
UA103907C2 (uk) Терапевтичний режим лікування гепатиту, який включає пег-інтерферон, рибавірин і vx-950
JO2861B1 (en) Use of 4-methoxy-propyl annular -N- - (3.5-dichloro-1-oxoperidine-4 yl) -5 (methoxy) pyridine-2-carboxamide in the treatment of brain tumors)
UA99163C2 (uk) Спосіб дозування ін'єкційної форми паліперидону пальмітату тривалої дії
SG146498A1 (en) Compositions for treatment of patients with neurological disorders and cerebral infarction